SanFran,

If Resverlogix and Zenith lacked any scheduled events over the next couple of months, I would agree with you more. However, the next couple of months already have some great opportunities for both Resverlogix and Zenith to gain exposure at both investment and science conferences. Additionally, we have been told that trial start dates for PNH and prostate cancer are imminent for Resverlogix and Zenith, respectively. Perhaps the companies are timing any major developments/news releases with these scheduled events.

Yes, many investors have been in on this for a long time. You mentioned 15 years. I haven't been in this for nearly as long. However, one must acknowledge both the good and the bad that has happened over this 15 years. I'm not going to chronicle the history here. We all should know it and if you don't you have some due diligence to take care of.

BET inhibitors still have a long way to go. There is no BET inhibitor that has been approved for prescribing for any condition. But through those bumps along the 15 year travel, Resverlogix has emerged as the only company with a bromodomain-2 selective BET inhibitor in clinical trials. And furthermore, Resverlogix has the only BET inhibitor in Phase 3 trials. And from realization of the BET inhibitor mechanism of action, which occured only relatively recenlty, Zenith Epigenetics was born (as an aside, website under construction?). And now, we are following two companies that are emerging as leaders in the BET inhibitor pharmaceutical field. I am optimistic that the Epigenetics: Cancer and Beyond event is going to be great exposure opportunity for both companies in late April.

So even if we don't get all of the answer to our questions in the Q1 webcast, keep in mind that a lot can change between now and the end of April.

The often overly optimistisc one,

BearDownAZ